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Abstract
Background: The telomeric region of mouse chromosome 12 has previously shown frequent
allelic loss in murine lymphoma. The Bcl11b gene has been identified and suggested as a candidate
tumor suppressor gene within this region. In this study, we aimed to elucidate whether Bcl11b is
mutated in lymphomas with allelic loss, and whether the mutations we detected conferred any
effect on cell proliferation and apoptosis.
Methods: Mouse lymphomas induced by 1,3-butadiene or 2',3'-dideoxycytidine were analysed for
mutations in the Bcl11b gene using single strand conformation analysis and direct DNA sequencing.
Effects on cell proliferation by the detected mutations were studied by expressing wild-type and
mutant Bcl11b in the cytokine-dependent hematopoietic progenitor cell line FDC-P1, lacking
endogenous Bcl11b expression.
Results:  Missense and frameshift (FS) mutations wer e  i d e n t i f i e d  i n  7  o f  4 7  t u m o r s  ( 1 5 % ) .
Interestingly, all mutations were found between amino acids 778–844 which encode the three C-
terminal DNA-binding zinc fingers. In FDC-P1 cells, wild-type Bcl11b suppressed cell proliferation,
whereas the mutated versions (S778N, K828T, Y844C and FS823) enhanced proliferation several-
fold.
Conclusion: The genetic alterations detected in this study suggest that the three C-terminal zinc
fingers of Bcl11b are important for the DNA-binding. Cell proliferation was suppressed by
overexpression of wild-type Bcl11b but enhanced by mutant Bcl11b, indicating that these mutations
may be an important contributing factor to lymphomagenesis in a subset of tumors.
Background
The  BCL11B/Rit1/CTIP2  gene was first identified in
human chromosome 14q32.2 [1], as a homologue to
BCL11A/CTIP1, which is known to be involved in translo-
cations in human leukemia [2,3]. In the immune system,
BCL11B is expressed exclusively in the T cells [4] and is
involved in both translocations [5] and inversions [6] in
human T-cell acute lymphoblastic leukemia (T-ALL).
Also, deletions in the Bcl11b gene have been detected in
radiation-induced lymphoma in mice that is caused by
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V(D)J recombinase activity [7]. Bcl11b-/- knockout mice
show a block at the immature stage of T-cell differentia-
tion, partly due to lack of pre-T-cell receptor (TCR) expres-
sion on the cell surface [4]. Introducing functional TCRβ
and TCRαβ-chains into Bcl11b-/- mice does not release this
differentiation block, suggesting another signaling mech-
anism required for differentiation of T cells [8].
BCL11B contains six DNA-binding zinc-finger structures
as well as a proline-rich domain and an acidic domain
that may possibly transactivate target genes [1]. Bcl11b
has been shown to be a strong transcriptional repressor in
vitro [9], and other groups have shown that Bcl11b inter-
acts with the histone deacetylase SIRT1 within a larger
protein complex in mammalian cells [10], and with the
nucleosome remodeling and deacetylase (NuRD) protein
complex in T lymphocytes [11]. Both SIRT1 and NuRD
bind to and deacetylate p53, thereby repressing p53-
mediated transactivation [12,13]. Recently, Cismasiu et.
al. [14] reported that Bcl11b initiates IL-2 transcription in
CD4+ T cells, contradictory to the previous report on
Bcl11b being a transcriptional repressor [9]. Bcl11b has
also been assigned anti-apoptotic properties, since knock-
down of Bcl11b expression with RNA interference
induced apoptosis in T-cell lines [15,16].
Murine Bcl11b shows 88% identity to the human BCL11B
at nucleotide level. Studies on chemically induced T-cell
lymphoma in mice have previously shown frequent allelic
loss in the telomeric region of chromosome 12 [17],
which is syntenic to human 14q32.2 and the location of
the Bcl11b gene. Another study revealed frequent muta-
tions in Bcl11b in radiation-induced lymphoma in mice
[18], supporting a role of Bcl11b in regulation of cell
growth. The present study identifies tumor specific point
mutations and microdeletions in chemically induced
mouse lymphoma. The mutations were functionally ana-
lysed by overexpression in the hematopoietic progenitor
cell line FDC-P1. Interestingly, wild-type Bcl11b was able
to suppress cell proliferation, whereas tumor specific
point mutations and frameshift mutations in Bcl11b
enhanced proliferation.
Methods
Materials
Sixteen 2',3'-dideoxycytidine-induced lymphoma in
C57Bl/6 × C3H/HeJ F1 (B6C3F1) mice (DLF) and thirty-
one 1,3-butadiene-induced lymphoma in B6C3 F1 mice
(BLF) were analyzed for mutations in the Bcl11b gene. The
tumors were kindly provided by R. Wiseman (National
Institute of Environmental Health Sciences, Research Tri-
angle Park, NC) and were induced by gavage of 2',3'-dide-
oxycytidine [19] or by inhalation of 1,3-butadiene [20]. In
total 47 lymphomas (31 BLF and 16 DLF) were collected,
all of T-cell origin [19,20]. DNA was purified as previously
described [17].
Mutation analysis
Mutations were detected with Single Strand Conforma-
tion Analysis (SSCA) and direct sequencing. The Bcl11b
gene was PCR-amplified for 35 cycles in the 47 tumor
samples and in normal spleen from B6C3F1 mice. Prim-
ers were designed to cover the complete coding sequence
of Bcl11b including exon/intron borders (Table 1). The
amplified DNA was radioactively labeled with [α-
32P]dATP (Amersham Pharmacia Biotech, Buckingham-
shire, UK) for 10 cycles, denatured and applied to a non-
denaturing 6% polyacrylamide gel containing 10% glyc-
erol and to an 0.5 × MDE™-gel (FMC BioProducts, Rock-
land, ME). Fragments with altered electrophoretic
mobility were excised from the gel, eluted in water and
reamplified for 35 cycles. The PCR product was purified
with ExoSAP-IT® (Amersham Biosciences, Uppsala, Swe-
den), labeled with DYEnamic ET Dye Terminator Cycle
Sequencing Kit for MegaBACE DNA Analysis Systems™
(Amersham Biosciences), following the manufacturer's
instructions, and applied to MegaBACE DNA Analysis Sys-
tems™ (Amersham Biosciences). Repeated mutation anal-
ysis from original DNA was performed on tumors to
confirm mutations.
Transfection of FDC-P1 and generation of Bcl11b 
expressing clones
cDNA corresponding to wild-type Bcl11b was PCR-ampli-
fied using the primers in Table 1 and ligated into the
expression vector pCI-neo (Promega, Madison, WI).
S778N, K828T, Y844C and FS823 were introduced into
the plasmid using the protocol of Quikchange (Strata-
gene, La Jolla, CA) and the primers presented in table 1.
Wild-type and mutant plasmids were then individually
transfected into the IL-3-dependent hematopoietic pro-
genitor cell line FDC-P1 by electroporation (260 V, 950
µF). Forty-eight hours post-transfection, 1,000 cells/well
were seeded on a 96-well plate in Iscove's modified Dul-
becco's medium (IMDM) supplemented with IL-3, 10 %
fetal calf serum and 1 mg G418/ml (Gibco) to select for
transfected cells. G418-resistant clones were picked,
expanded, and tested for expression of Bcl11b by RT-PCR
and Western blot. RNA was isolated from the cells using
Trizol® reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer's instructions. RT-PCR was performed by an
initial denaturation of 5 µg of RNA and 0.25 µg random
primers (Invitrogen) in 11.5 µl volume for 10 minutes at
70°C. To this sample, 200 U RT Superscript (Invitrogen)
and 13 U RNAguard (Amersham Biosciences) was added
in a total volume of 20 µl of 1 × buffer (Invitrogen), 0.5
mM dNTP, 0.01 M dithiothreitol (final concentrations),
prior to incubation at 42°C for 50 minutes and then 70°C
for 15 minutes. The cDNA was used for PCR with primersBMC Cancer 2007, 7:195 http://www.biomedcentral.com/1471-2407/7/195
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ex2bF and zfd1R (Table 1). For Western blot analysis, cells
were lysed in RIPA buffer and the protein fraction was sep-
arated on a 4–12% gradient PAGE gel (Invitrogen) and
blotted to a PVDF membrane. Bcl11b expression was
detected with antibodies against human BCL11B (Bethyl
Laboratories Inc., Montgomery TX), showing partial cross-
reactivity to mouse Bcl11b.
FACS analysis of cell survival
FDC-P1 cells were washed twice in PBS and twice in PBS
with 10% FCS and seeded in a 24 well plate (1 ml/well) at
the initial density of 5 × 105 cells/ml and in the absence of
IL-3. After 24, 48 and 72 hours of incubation at 37°C and
5% CO2, cells were washed twice in PBS and the propor-
tion of dead cells measured by flow cytometry on a FACS
Calibur flow cytometer (Becton Dickinson, San Jose, CA)
after staining cells in 0.8 µg/ml of propidium iodide (final
concentration).
Determination of cell proliferation
Cells were washed twice in PBS and twice in PBS with 10%
FCS, and then cultured at 1 × 104/well in 96-well flat-bot-
tom microtiter plates. Cultures were maintained for 72
hours at 37°C and 5% CO2 in IMDM supplemented with
10% FCS and stem cell factor (SCF; PeproTech EC Ltd.,
London, UK) at 100 ng/ml. At the end of the experiment,
cultures were labeled for 6 hours with 0.5 µCi/well [3H]-
Table 1: Primers used for mutation analysis, sequencing, cloning and mutagenesis of mouse Bcl11b.
Fragment Direction Sequence (5'->3') Size of PCR 
product (bp)
Annealing temp.
 (°C)/Cycles
ex1 F CGC ATC TGT GCA GCT TTC 226 56/35
R CCG GCT GCA GAG AAA CTT
ex2a F TGT CTT CTC TGC CCC TTC C 264 59/35
R CTT GTC CAG GAC CTT GTC GT
ex2b F ACC TGT GGC CAG TGT CAG AT 300 59/35
R TAG GGA GGC AGC TTC AGC A
ex3 F GGC ACC ACT GAC CAG TCT TT 377 61/35
R CTT TTT GAG TGG GGG ATG G
zfd1 F TGC TCA CAC TCT GCC TTT CTT 291 59/35
R GCA GCA GGT TGA AAG GAT TG
ex4a F TGA ATT TCC TGG GGG ACA G 283 60/35
R CTG TTG CCG GCC AGT TCT
prd F TCT CCT GCC ATG GAC TTC TC 329 62/35
R TGG CAC TTG TAG GGC TTC TC
zfd2 F AGT CCC AAG TCC CCG TTC 299 60/35
R CAG CTG AGA GCC CGT CGT
acd F ATG AAG ACG CAC ATG CAC AA 289 64/35
R CAC GCC ACC TCC GTT CTC
ex4b F AGC ATG GAC TCG GAG CTG 300 62/35
R AGC TGG AAA GGG CTC TGC
ex4c F GTG ATG CCG GAG CTG TTG 291 59/35
R CCA GGA ATG GGT CCT TCA
ex4d F GTG TAC TCG CAG TGG CTC GT 294 60/35
R GAC CTT GCC GCA GTA CTC AC
zfd3 F ACA CCT CAC CTG GGT GGT C 274 59/35
R TCA TTA GTC AGC AAG TGT TCA CC
cloning F TTT GAA TTC ATG TCC CGC CGC AAA C 2459 65/35
R TTT GCG GCC GCT TAG CTC CTC TCA GCC TGC TC
S778N F CTG GGA GGC CGA ACT CCA AGG AGG GC 65/12
R GCC CTC CTT GGA GTT CGG CCT CCC AG
K828T F GCA GAG CAG CAC GCT CAC GCG CCA C 65/12
R GTG GCG CGT GAG CGT GCT GCT CTG C
Y844C F GCA AGG AGG TGT GCC GCT GCG ACA TC 65/12
R GAT GTC GCA GCG GCA CAC CTC CTT GC
FS823 F CGA GCT GTG CAA CTA CGC GCT AAG AGC AGC AAG CTC ACG 
CG
65/18
R CGC GTG AGC TTG CTG CTC TTA GCG CGT AGT TGC ACA GCT 
CGBMC Cancer 2007, 7:195 http://www.biomedcentral.com/1471-2407/7/195
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thymidine (Amersham Biosciences), harvested, and
counted in a β-scintillation counter.
CFSE staining
CFSE, 5-(and-6)-carboxyfluorescein diacetate succinimi-
dyl ester (Molecular Probes, Eugene, OR), stock solution
(5 mM in DMSO) was diluted 1:1000 in IMDM (no FCS).
Cells were washed in PBS and then resuspended in CFSE/
IMDM for 8 minutes at room temperature in the dark.
Labeling was quenched by adding the same volume of
FCS, inverting the tube for 2–3 seconds followed by cen-
trifugation. Cells were washed four times in IMDM with
FCS (10 %), and then cultured in 100 ng/ml SCF. After 72
hours, cells were washed once in PBS and analyzed for
CFSE staining on a FACSCalibur cytometer (Becton Dick-
inson) on the FL-1 channel using log amplification.
Results
Forty-seven chemically induced lymphomas were ana-
lysed for mutations in the Bcl11b gene by SSCA and Meg-
aBACE sequencing. In total, seven of 47 tumors (15%)
revealed mutations, of which six were missense mutations
and one was a frameshift mutation. BLF17 displayed a 7
bp-deletion and a 3 bp-insertion, causing a frameshift
mutation in codon 823 and a premature truncation at
codon 832. The truncation results in deletion of two C-ter-
minal zinc fingers of the Bcl11b protein. Interestingly,
four samples (BLF3, BLF4, BLF15 and DLF16) displayed
A>C mutations in base 2483, indicating a hotspot site for
mutations in 1,3-butadiene and 2',3'-dideoxycytidine
induced lymphomas. This mutation results in an
exchange of the basic amino acid lysine to the neutral
threonine in codon 828. This codon is located in the fifth
zinc finger of the Bcl11b protein, which may be important
for DNA binding to target genes. DLF1 showed an A>G
mutation at base 2531 with a subsequent tyrosine to
cysteine substitution in codon 844. The functional conse-
quence of this amino acid shift is unknown, but the shift
occurs only two amino acids away from one of the zinc-
binding cysteines in the sixth zinc finger and may affect
the structure of the zinc fingers and thus the DNA-bind-
ing. BLF22 revealed a G>A mutation in base 2333, result-
ing in a serine to asparagine substitution in codon 778.
This amino acid is not included in any of the zinc fingers,
but the change from a serine could possibly result in loss
of a phosphorylation site, which would interfere with the
function of the protein.
To elucidate if any of these mutations influence cell func-
tion, FDC-P1 cells were transfected with either wild-type
Bcl11b or any of three point mutated versions of Bcl11b
(S778N, K828T and Y844C). We chose FDC-P1 cells for
these experiments due to lack of endogenous Bcl11b
expression and because of the wide use of this cell line to
study proliferation and apoptosis in hematopoietic cells.
FDC-P1 cells are dependent on IL-3 for continuous
growth but are responsive to other cytokines such as SCF
by slower cell cycle kinetics and inhibition of apoptosis.
In addition, SCF can synergize with other stimuli to
enhance proliferation [21]. Multiple clones were gener-
ated for either wild-type Bcl11b or the different mutants
after selection in G418. For subsequent analyses, however,
only few clones were chosen for each case. Expression was
first detected by RT-PCR (Figure 1A). To quantify the
amount of Bcl11b expression, Western blots were per-
formed using an antibody against human BCL11B which
displays some cross-reactivity to mouse Bcl11b (Figure
1A). The clones were initially grown in the absence of
cytokines to analyze the ability to sustain survival as meas-
ured by propidium iodide staining followed by flow
cytometry. However, none of the clones were able to sup-
port survival (Figure 1B). In addition, Bcl11b was ana-
lyzed for synergistic effects in combination with SCF by
[3H]-TdR incorporation. Interestingly, FDC-P1 cells trans-
fected with the non-mutated Bcl11b gene showed a two-
three-fold suppression of proliferation compared to non-
transfected cells (Figure 1C). In contrast, K828T, S778N
and Y844C were able to enhance SCF-induced prolifera-
tion two-three-fold compared to non-transfected FDC-P1
(Figure 1C).
To confirm that the wild-type Bcl11b gene inhibits and
that the mutants enhance proliferation, we measured cell
cycle progression of FDCP-1 cells by staining them with
the fluorescent marker CFSE. In this assay, we also tested
whether the truncated mutant FS823 had effects on cell
proliferation. After culturing the cells for 72 hours in the
presence of SCF and CFSE, we performed flow cytometric
analysis. This is a widely used method to assess prolifera-
tion rate, since the intensity of the CFSE stain gradually
decreases as cells divide. As seen in Figure 1D, the inten-
sity of CFSE is diminished in cells transfected with mutant
K828T and Y844C, whereas the S778N mutant did not
differ compared to untransfected cells. This is in agree-
ment with the results from the [3H]-TdR incorporation
(Figure 1C), where the S778N mutant did not increase
proliferation much compared to non-transfected cells.
Three individual clones carrying the FS823 mutation were
also included in this proliferation assay, where they dis-
played a similar decrease as K828T and Y844C (only data
from one clone is shown in Figure 1D). Importantly, cells
transfected with wild-type Bcl11b displayed higher CFSE
intensity than untransfected FDCP-1, indicating that these
cells have passed through fewer cell cycles.
Apart from identifying mutations in the Bcl11b  gene,
sequencing also revealed two polymorphic sites (729A>G
and 1386G>A) in the C3H/HeJ strain compared to the
C57Bl/6J strain. Neither of the polymorphisms results in
amino acid change and is therefore not likely to affect theBMC Cancer 2007, 7:195 http://www.biomedcentral.com/1471-2407/7/195
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Overexpression of Bcl11b inhibits proliferation of the hematopoietic progenitor cell line FDC-P1 but has no effect on apoptosis Figure 1
Overexpression of Bcl11b inhibits proliferation of the hematopoietic progenitor cell line FDC-P1 but has no 
effect on apoptosis. (A) Expression of Bcl11b in FDC-P1 and cells transfected with the mutated versions K828T, S778N, 
Y844C and FS823 was detected by Western blot and RT-PCR. In the Western blot analysis, the human cell line Jurkat was 
included as a positive control. The two bands correspond to different isoforms of Bcl11b. (B) Cell viability was determined by 
staining with propidium iodide followed by flow cytometric analysis. Data shown are the mean ± SD (n = 6). (C) Proliferation 
of non-transfected FDC-P1 cells and FDC-P1 cells transfected with wild-type Bcl11b or the mutated versions (K828T, S778N 
or Y844C) was measured by [3H]-TdR incorporation (cpm × 10-3) after 72 hours of SCF-stimulation. Results are presented as 
mean ± SD (n = 3). FDCP1: 11.8 ± 1.7; wild-type Bcl11b: 4.4 ± 1.1; K828T: 37.5 ± 3.3; S778N: 19.3 ± 1.9; Y844C: 32.4 ± 0.9. 
(D) Cells were stained with CFSE and cultured for 72 hours in SCF, after which CFSE fluorescence was determined by flow 
cytometry. Histograms for the four different mutants K828T, S778N, Y844C and FS823 (K, S, Y and FS, respectively) are 
shown. CFSE fluorescence declines (shift to the left on the X-axis) as cell numbers increase. In each histogram, data from non-
transfected FDC-P1 cells (F) and cells transfected with wild-type Bcl11b (wt) are overlaid for a comparison. Results are from 
one representative experiment of three performed.
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function. These polymorphisms enabled us to confirm
previously detected allelic loss in chromosome 12 in 16
out of 47 samples [17] (Figure 2). None of the Bcl11b
mutated samples coincided with the samples showing
allelic loss, contradictory to previous reports on muta-
tions in Bcl11b [18].
Discussion
The region on mouse chromosome 12 where Bcl11b is
located has previously shown frequent allelic loss in
murine lymphomas [17]. The role of Bcl11b in lymphom-
agenesis is also indicated by studies showing Bcl11b muta-
tions in radiation-induced mouse lymphomas [18] as well
as inversions and translocations involving Bcl11b  in
human T-ALL [5,6]. This is further supported in the
present study, where 15% (7/47) of chemically induced
murine lymphoma (13% of DLF and 16% of BLF) display
somatic mutations in Bcl11b. Interestingly, all mutations
are located between codon 778 and 844, with a hotspot at
codon 828 where four samples show the same mutation
(Table 2). This region of Bcl11b contains three of the six
zinc finger structures, which concomittant with studies on
other zinc-finger containing transcription factors are
likely to be important for the DNA-binding function of
the protein. The frameshift mutation was detected in the
same region, deleting the two C-terminal zinc fingers.
To test whether the mutations detected in this study had
any effect on cell growth, FDC-P1 cells lacking endog-
enous expression of Bcl11b were transfected with either
wild-type  Bcl11b  or any of the four mutants S778N,
K828T, Y844C or FS823. FDC-P1 cells overexpressing
wild-type Bcl11b showed reduced proliferation rate with
more than 50% compared to non-transfected cells. Over-
expression of the K828T, Y844C and FS823 mutated vari-
ants of Bcl11b resulted in increased proliferation both
with thymidine incorporation (Figure 1C) and with CFSE
staining (Figure 1D). Interestingly, the K828T mutation
that was detected in four tumor samples seemed to
increase proliferation rate most efficiently among the
three different missense mutants. In addition, the
frameshift mutant also increased cell growth to the same
extent as K828T. These data demonstrate that the muta-
Allelic loss of the C3H allele or the B6 allele on chromosome  12 in BLF and DLF Figure 2
Allelic loss of the C3H allele or the B6 allele on chro-
mosome 12 in BLF and DLF. Two polymorphic sites 
(729A>G and 1386G>A) were found in Bcl11b, confirming 
previously detected allelic loss in D12Mit181 and D12Mit133 
[17]. Markers analyzed are shown on the left side of the 
chromosome and the distance of the marker from the cen-
tromere is presented on the right side of the chromosome. 
Black square indicates loss of the C3H allele; white circle 
indicates loss of the B6 allele; absence of circle or square 
indicates retention of heterozygosity. CEN, centromere; 
TEL, telomere.
TEL
CEN
BLF DLF
 1   5   6   7   8  11 15 20  2   3   6   8  11 12 13 14 15
 52.0 cM
D12Mit133 52.6 cM
D12Mit181 50.3 cM
Bcl11b , 1386
Bcl11b , 729
Table 2: Summary of genetic alterations of the Bcl11b gene in BLF and DLF.
Samples Mutations in Bcl11b (n = 47) Mutations in p53a
Nucleotide Amino acid
DLF
1 2531A>G Y844C
16 2483A>C K828T
BLF
3 2483A>C K828T
4 2483A>C K828T
7 N236S
8 C173F
9 Frameshift
10 H176L
12 Frameshift
15 2483A>C K828T
17 2467TGCGCGC>CTA Frameshift in codon 823
22 2333G>A S778N
25 R153G
aMutations of p53 have previously been analyzed and reported [26].BMC Cancer 2007, 7:195 http://www.biomedcentral.com/1471-2407/7/195
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tions identified in the present study are functional and
affect cell proliferation.
Allelic loss has previously been analyzed in the tumors of
this study [17] and the LOH was here confirmed by two
intragenic single nucleotide polymorphisms in Bcl11b
identified during the present mutation analysis on Bcl11b
(Table 2). Wakabayashi et al [18] has previously detected
point mutations and allelic loss in radiation-induced lym-
phoma in agreement with a two-hit hypothesis. However,
none of the samples in this study with mutations in
Bcl11b showed simultaneous allelic loss (Figure 2; Table
2). Kamimura et. al. [22] suggests that Bcl11b may be hap-
loinsufficient for suppression of tumors, since Bcl11b+/-
p53+/- mice generates more spontaneous tumors than do
Bcl11b+/+p53+/- mice. The phenomenon of haploinsuffi-
ciency, where one single copy of the gene may be incapa-
ble of providing sufficient protein in order to maintain
normal cell function, may explain the findings of our
study. It has previously been demonstrated for other
tumor suppressors as well, e.g. PTEN [23] and Smad4
[24].
Our study adds novel information on the growth enhanc-
ing effect of mutated Bcl11b. Our results are also in agree-
ment with the report by Wakabayashi et al. [18]
demonstrating the ability of non-mutated Bcl11b to sup-
press tumor growth when introduced into HeLa cells.
These authors identified similar but not identical muta-
tions in the Bcl11b gene in radiation-induced mouse lym-
phomas. Deletions were also detected in the radiation-
induced lymphomas, however, these were later found also
in normal thymocytes at an equal frequency [7].
The mechanisms by which Bcl11b execute growth sup-
pression is still unknown. However, a previous report has
demonstrated that Bcl11b is able to repress transcription
from a consensus response element [9], supporting our
notion of a suppressive role for Bcl11b on cell cycle. The
same group has recently proved that Bcl11b directly acti-
vates IL-2 expression in CD4+ T lymphocytes [14]. How-
ever, it is possible that the protein may have both
activating and repressing functions depending on which
other proteins it associates with and in which cell type it
is expressed. This has been described for other zinc finger
proteins that are important for T cell proliferation and dif-
ferentiation, e.g. Ikaros, which represses transcription by
binding to the NuRD complex, but may also potentiate
gene expression by binding to other proteins [25].
In the study on radiation-induced mouse lymphomas,
mutations in Bcl11b were found to be mutually exclusive
with p53 mutations, suggesting a common pathway for
tumor formation [18]. Of the 47 tumors analyzed in this
study, 13 revealed mutations in either Bcl11b or p53 [26]
(Table 2), but no tumor carried mutations in both genes,
supporting mutational complementarity. Furthermore,
Bcl11b has been shown to interact with the histone
deacetylase protein complex designated NuRD [11],
which reduces the levels of acetylated p53, repressing p53
dependent transcription and thereby modulating p53-
mediated cell growth arrest and apoptosis [13]. Likewise,
the interaction between Bcl11b and another histone
deacetylase, SIRT1 [10], also leads to transcriptional
repression of p53 [12]. However, due to the effects on pro-
liferation detected in the present study it is possible that
Bcl11b may act by an alternative mechanism.
Conclusion
The genetic alterations detected in this study suggest that
the three C-terminal zinc fingers of Bcl11b are important
for the DNA-binding. Cell proliferation was suppressed
by overexpression of wild-type Bcl11b but enhanced by
overexpression of mutant Bcl11b, suggesting that these
mutations may be an important contributing factor to
lymphomagenesis in a subset of tumors. However, future
studies are necessary to elucidate the exact function of
Bcl11b.
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